Golden
Autolus

Autolus

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Autolus develops and commercializes engineered T-cell immunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.



T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes. 

Timeline

People

Name
Role
Related Golden topics

Dr. Christian Martin Itin

Chairman, CEO



Dr. Jim Faulkner, PhD

Head of Manufacturing



Dr. Louise Holliday

Head of Intellectual Property



Dr. Martin Pulé

Founder, CSO



Mr. Christopher Vann

COO



Further reading

Title
Author
Link
Type

Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

Autolus Therapeutics plc

Web

Biotech to create 170 jobs, invest $28M in new Rockville HQ

Katie Arcieri

Web

Vineti announces strategic partnership with Autolus Therapeutics to support delivery of novel T cell therapies

Vineti

Web

Documentaries, videos and podcasts

Title
Date
Link

Cell Therapy Commercialization in Oncology

January 8, 2019

Companies

Company
CEO
Location
Products/Services









References